08:04 AM EDT, 06/07/2024 (MT Newswires) -- BWX Technologies' ( BWXT ) BWXT Medical subsidiary said Friday that it has submitted a drug master file to the US Food and Drug Administration for no-carrier added Actinium-225 active pharmaceutical ingredient, an isotope used in therapies to kill cancer cells.

Actinium-225 has been used in an early clinical study, and the drug master file is intended to be used as a reference for further clinical studies and eventually new drug applications, the company said.

Price: 89.88, Change: +0.19, Percent Change: +0.21